Results 111 to 120 of about 57,759 (194)

A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma

Cancer, Volume 132, Issue 4, 15 February 2026.
Abstract Background Pembrolizumab is approved for advanced cutaneous melanoma (aCM). Cabozantinib, an oral multi‐tyrosine kinase inhibitor, has demonstrated antitumor activity as monotherapy or in combination with anti‐PD‐1 therapy in malignancies. The objective of this study was to determine the safety and efficacy of cabozantinib and pembrolizumab ...
Yousef Zakharia, Donghyun Kim, Michele Freesmeier, Melanie Frees, Sarah Mott, Varun Monga, Douglas Laux, Asad Javed, John Rieth, John Smestad, Mohammed Milhem   +10 more
wiley   +1 more source

Retraction Note: Magnetic and pH sensitive nanocomposite microspheres for controlled temozolomide delivery in glioblastoma cells. [PDF]

Sci Rep
Ahmadi M, Ashoub MH, Heydaryan K, Abolghasemi S, Dawi EA, Khajouei G, Amiri M.   +6 more
europepmc   +1 more source

Positively Charged Polymers Based on Cyclodextrins for Trametinib and Selumetinib Delivery in Glioblastoma Cancer

ChemMedChem, Volume 21, Issue 3, 12 February 2026.
β‐cyclodextrin‐based multicharged polymers—linear or cross‐linked—enhance the delivery of mitogen‐activated protein kinase inhibitors (selumetinib, trametinib) in glioblastoma cells. These carriers enhance the antiproliferative effect of the drugs and strengthen extracellular signal‐regulated kinase pathway inhibition.
Noemi Bognanni, Maria Teresa Gentile, Antonia Feola, Valentina Giglio, Martina Dragone, Carla Isernia, Graziella Vecchio   +6 more
wiley   +1 more source

Venous Thromboembolism and Bleeding with Temozolomide-, Bevacizumab-, and Nitrosourea-Based Therapy in Glioma: A Dual-Database Pharmacovigilance Study. [PDF]

Cancers (Basel)
Hou X, Zhang Y, Liang C, Yao S.
europepmc   +1 more source

Defying the Odds in Recurrent Glioblastoma: Complete Response following Salvage Therapy with Bevacizumab and Irinotecan - A Case Report. [PDF]

Case Rep Oncol
Yousefi A, Saraee E, Ghalehtaki R.
europepmc   +1 more source

MGMT upregulation mediates Temozolomide resistance conferred USP5 dependency. [PDF]

Sci Rep
Bhardwaj S, Sanjay, Sharma D, Taneja L, Yadav BK, Yadav AK.   +5 more
europepmc   +1 more source

Impact of neuroendocrine neoplasm-specific systemic treatments on expression and function of CXCR4 in neuroendocrine tumor cells. [PDF]

Sci Rep
Däubler C, Böttcher C, Landwehr LS, Meining A, Michalski K, Reiter F, Werner RA, Hartrampf P, Rogoll D, Weich A.   +9 more
europepmc   +1 more source

Retraction Note: Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. [PDF]

Sci Rep
Bai Y, Chen Y, Hong X, Liu X, Su X, Li S, Dong X, Zhao G, Li Y.   +8 more
europepmc   +1 more source

Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor. [PDF]

Curr Oncol
Guo J, Lewis KA, Prakash L, Bhosale P, Morani A, Katz MHG, Tzeng CD, Ikoma N, Snyder R, Kim MP, Chandrasekharan C, Dasari A, Yao JC, Lee JE, Maxwell JE, Halperin DM.   +15 more
europepmc   +1 more source

Effects of temozolomide dosing on outcome in glioblastoma. [PDF]

J Neurooncol
Raghu A, Killar S, Cohen AL.
europepmc   +1 more source